Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.

抗凝血酶 药代动力学 药理学 化学 医学 肝素 抗凝剂 半衰期
作者
Bernard Boneu,Necciari J,Roger Cariou,Pierre Sie,Gabaig Am,Kieffer G,Dickinson Jp,Lamond G,H. C. T. Moelker,Mant T
出处
期刊:Thrombosis and Haemostasis [Georg Thieme Verlag KG]
卷期号:74 (6): 1468-1473 被引量:132
标识
DOI:10.1055/s-0038-1649967
摘要

Abstract This paper reports the results of the first administration of the synthetic natural pentasaccharide with high affinity to antithrombin III (NP) in man. This study was mainly focused upon the pharmacokinetic properties and general tolerance of the compound. Subcutaneous injections of doses < 1.43 mg (1000 anti Xa IU) did not generate measurable anti-Xa activities. After subcutaneous injection of increasing doses from 1.43 to 22.9 mg (1000 to 16,000 anti-Xa IU) to young healthy volunteers, it was found that the maximal concentration (Cmax) and the area under curve (AUC) were linearly correlated to the dose, that the total plasma clearances (CI) were constant and almost 3 times lower than those of the current low molecular weight heparins. Cmax were reached between 1 h and 3 h after the injection and the half-lives (t 1/2) were remarkably constant (13.1 h to 13.9 h). During the first 24 h following the injection, around 50% of the total administered dose was recovered in the urine in an active form, indicating that kidney plays a major roles in the elimination of NP. Consistent with these results, when NP was administered to healthy elderly volunteers having a lower creatinine clearance, the half-life of the compound was longer and the clearance lower. At doses exceeding 22.9, Cmax, and AUC were slightly lower than expected, the percentage of the dose recovered in the urine and the total apparent plasma clearance increased, suggesting that the excess of NP unbound to antithrombin III was excreted faster. NP was also administered at various dosages once or twice a day for 7 days to 20 elderly volunteers. Due to the long half-life of the compound the steady state was obtained 2 to 3 days after the first injection at which the mean Cmax was increased 1.5 to 2 times. The general tolerance of the compound was excellent. No relevant prolongations of the prothrombin time, of the activated partial thromboplastin time or of the bleeding time were observed. A re-bleeding phenomenon of the bleeding time incision, probably related to friability of the haemostatic plug, occurred in 3 subjects treated with the highest dose regimens: single injection of 26.6 mg (20,000 anti-Xa IU) (young volunteers) and repeated injections of 11.4 mg (8,000 anti-Xa IU) once a day for 7 days (elderly volunteers). At these times, plasma NP concentrations were between 2.9 and 3.6 micrograms.ml-1 (2 and 2.5 anti-Xa IU.ml-1).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT应助靜心采纳,获得10
刚刚
刚刚
刚刚
大大小小发布了新的文献求助10
1秒前
大先生完成签到 ,获得积分10
1秒前
浮生完成签到 ,获得积分10
1秒前
2秒前
憧憬未来完成签到,获得积分10
3秒前
无花果应助二宝采纳,获得10
3秒前
飘逸问薇完成签到 ,获得积分10
3秒前
3秒前
ipan918完成签到,获得积分10
5秒前
李爱国应助刻苦沛芹采纳,获得10
5秒前
卑微学术人完成签到 ,获得积分10
5秒前
6秒前
细心的冰淇淋完成签到,获得积分10
6秒前
深海完成签到,获得积分20
6秒前
7秒前
lianlian完成签到,获得积分10
8秒前
田様应助cuicui采纳,获得10
10秒前
Soybean完成签到 ,获得积分10
10秒前
FashionBoy应助大大小小采纳,获得10
10秒前
10秒前
仇行恶完成签到,获得积分20
10秒前
12秒前
靜心发布了新的文献求助10
12秒前
大先生完成签到,获得积分10
13秒前
米某某完成签到,获得积分10
14秒前
萧水白发布了新的文献求助100
14秒前
15秒前
15秒前
Mor完成签到,获得积分20
15秒前
16秒前
16秒前
16秒前
仇行恶发布了新的文献求助10
16秒前
17秒前
17秒前
emo发布了新的文献求助30
17秒前
张朵拉关注了科研通微信公众号
17秒前
高分求助中
Evolution 10000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3147820
求助须知:如何正确求助?哪些是违规求助? 2798873
关于积分的说明 7832037
捐赠科研通 2455841
什么是DOI,文献DOI怎么找? 1306979
科研通“疑难数据库(出版商)”最低求助积分说明 627957
版权声明 601587